glaumox acetazolamide (as sodium) 500 mg powder for injection vial
phebra pty ltd - acetazolamide sodium, quantity: 549.5 mg (equivalent: acetazolamide, qty 500 mg) - injection, powder for - excipient ingredients: sodium hydroxide; hydrochloric acid - for adjunctive treatment of: oedema due to congestive heart failure; drug induced oedema; centrencephalic epilepsies (petit mal, unlocalised seizures); chronic simple (open-angle) glaucoma, secondary glaucoma and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure.
remsima 100mg powder for concentrate for solution for infusion vials
napp pharmaceuticals ltd - infliximab - powder for solution for infusion - 100mg
brevibloc esmolol hydrochloride 2.5 g powder for injection for infusion vial
phebra pty ltd - esmolol hydrochloride, quantity: 2500 mg - injection, powder for - excipient ingredients: - supraventricular tachycardia,brevibloc (esmolol hcl) is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. brevibloc is also indicated in non compensatory sinus tachycardia where, in the physician's judgement, the rapid heart rate requires specific intervention. brevibloc is not intended for use in chronic settings where transfer to another agent is anticipated or for treatment periods greater than 24 hours duration.
geepenil vet 300 mg/ml powder and solvent for solution for injection
orion corporation - benzylpenicillin sodium - powder and solvent for solution for injection - antimicrobial - horses
geepenil vet 300 mg/ml powder for solution for injection
orion corporation - benzylpenicillin sodium - powder for solution for injection - antimicrobial - horses
abraxane nanoparticle albumin-bound paclitaxel 100 mg powder for injection (suspension) vial
abraxis bioscience australia pty ltd - paclitaxel, quantity: 100 mg - injection, powder for - excipient ingredients: albumin; sodium octanoate; sodium acetyltryptophanate - metastatic breast cancer abraxane is indicated for the treatment of metastatic carcinoma of the breast after failure of anthracycline therapy. non-small cell lung cancer abraxane, in combination with carboplatin, is indicated for the first-line treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation. metastatic adenocarcinoma of the pancreas abraxane, in combination with gemcitabine, is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas.
herzuma 150mg powder for concentrate for solution for infusion vials
napp pharmaceuticals ltd - trastuzumab - powder for solution for infusion - 150mg
abraxane nanoparticle albumin-bound paclitaxel 250 mg powder for injection (suspension) vial
abraxis bioscience australia pty ltd - paclitaxel, quantity: 250 mg - injection, powder for - excipient ingredients: albumin; sodium octanoate; sodium acetyltryptophanate - metastatic breast cancer abraxane is indicated for the treatment of metastatic carcinoma of the breast after failure of anthracycline therapy. non-small cell lung cancer abraxane, in combination with carboplatin, is indicated for the first-line treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation. metastatic adenocarcinoma of the pancreas abraxane, in combination with gemcitabine, is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas.
ipecac syrup a.p.f. oral liquid
orion laboratories pty ltd t/a perrigo australia - cephaelis ipecacuanha -
norlevo-1 levonorgestrel 1.5 mg tablet blister pack
orion laboratories pty ltd t/a perrigo australia - levonorgestrel, quantity: 1.5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; maize starch; colloidal anhydrous silica; lactose monohydrate; povidone - oral emergency contraceptive indicated for use within 72 hours of unprotected intercourse. it should be used only as an emergency measure. women who present for repeated courses of emergency contraception should be advised to consider long-term methods of contraception.